Limosilactobacillus fermentum (Lactobacillus fermentum)
Limosilactobacillus fermentum, formerly Lactobacillus fermentum, is a lactic acid bacterium sold as named strains, and the research is strain by strain, so a result for one strain does not carry over to another. Strain VRI-003 (sold as PCC) was tested in athletes: 20 male runners had fewer respiratory symptom days than on placebo, while a larger cyclist trial co-funded by its marketers could not show a clear effect; the strain has its own page. Strain CECT5716, from breast milk, was tested in nursing women with breast pain, around flu vaccination and in infant formula. Strain ME-3 was tested on blood antioxidant and lipid markers, including an 8 week kefir trial that fewer than half of those enrolled finished. Strain MN-LF23 was tested alongside drug therapy for H. pylori. Most trials are small and several involved the maker. Each strain's own page covers its evidence in full.
Benefits
Respiratory symptom days in elite distance runners (strain VRI-003, sold as PCC)
In a double-blind, placebo-controlled crossover over 4 months of winter training, 20 elite male runners taking strain VRI-003 at a daily dose of 1.26 x 10^10 reported 30 days of respiratory symptoms on the strain versus 72 on placebo. Salivary IgA, the immune measure the trial set out to raise, did not change. The Lactobacillus fermentum PCC (VRI-003) page covers this strain's evidence.
Respiratory and gut symptoms in competitive cyclists (strain VRI-003)
In 99 cyclists (88 analyzed) taking at least 1 x 10^9 CFU of strain VRI-003 a day for 11 weeks, the effect on upper respiratory symptoms, a main aim, was too uncertain to call. In a split by sex, lower respiratory symptom load was about one third of placebo in men but was higher, with wide uncertainty, in women. Mild gut symptom episodes were about twice as frequent on the strain. The marketers co-funded it. See the PCC (VRI-003) page.
Breast comfort in nursing women (strain CECT5716)
In a maker-run, double-blind trial in nursing women with painful breastfeeding, breast pain scores, a secondary outcome, were lower than placebo at all three doses of strain CECT5716 after 3 weeks. The main outcome, Staphylococcus counts in milk, fell from baseline while the placebo group stayed similar. The doses worked alike, so no dose response was seen. See the CECT5716 page.
Immune markers after flu vaccination in adults (strain CECT5716)
In 50 healthy adults taking strain CECT5716 for 2 weeks before and 2 weeks after a flu shot, natural killer cells rose in the probiotic group but not on placebo, and flu-specific IgA rose only with the probiotic. Influenza-like illness over 5 months was reported as lower, with no statistics given in the abstract. These are immune markers from one small trial whose first author worked for the strain's company.
Gut health in formula-fed infants (strain CECT5716)
In infants fed a follow-on formula from 6 to 12 months, adding strain CECT5716 to a formula that already contained galactooligosaccharides was followed by a 46% lower rate of gut infections. The reported respiratory and total infection results are uncertain because the published statistics for them do not fit together. This is evidence in babies, not in adults taking a capsule.
Digestive comfort during antibiotic therapy (strain MN-LF23)
In 94 adults with a diagnosed H. pylori infection, strain MN-LF23 was taken alongside 14 days of prescribed quadruple drug therapy and for 4 weeks after. It did not change whether the infection cleared, but digestive symptom scores, constipation and indigestion were lower than on placebo. This is an add-on to drug treatment for an infection, not a test of the strain on its own. Two authors worked for a dairy company.
Blood antioxidant markers in healthy adults (strain ME-3)
In a 3 week double-blind trial in 24 healthy adults, strain ME-3 capsules raised blood total antioxidative activity and status from baseline, only 4% and 2.5% more than placebo, with no between-group test reported. In a 21 person open study, goat milk fermented with ME-3 and plain goat milk both raised these markers. These are lab markers from the strain's developers; see the ME-3 page.
Skin severity scores in young children (strain VRI-003)
In a placebo-controlled trial in 56 children aged 6 to 18 months with moderate or severe atopic dermatitis, severity scores fell over time with 1 x 10^9 bacteria of strain VRI-003 twice daily for 8 weeks but not with placebo. At 16 weeks, 92% versus 63% scored better than at baseline. The abstract reports no direct between-group score comparison. See the PCC (VRI-003) page.
Blood lipid markers (strains PCC and ME-3)
Results differ by strain. In a 10 week placebo-controlled trial in 46 adults, strain PCC did not change LDL, total cholesterol, HDL or triglycerides more than placebo. In an 8 week kefir trial, ME-3 lowered LDL 5% and triglycerides 17%, more than plain kefir, but only 76 of 164 people finished. These are blood markers, not heart outcomes; see the PCC and ME-3 pages.
Mechanism of action
Each strain has its own traits
L. fermentum is a species, and each trial on this page tested one named strain. ME-3 was chosen for antioxidant activity in lab tests, CECT5716 was isolated from breast milk, and VRI-003 (PCC) was supplied for trials by the Australian company Probiomics. A result for one strain cannot be assumed for another, or for an unnamed L. fermentum on a label.
Passes through and adds to gut lactobacilli
In the ME-3 studies, total stool lactobacilli rose, although ME-3 itself was recovered from stool only when taken in fermented milk. In the VRI-003 cyclist trial, stool lactobacilli rose clearly more than on placebo in men, while the rise in women was unclear. This suggests the bacteria survive the gut journey for a time; it does not show lasting colonization.
Signals to the immune system
In the flu vaccine trial, strain CECT5716 was linked to a rise in natural killer cells and larger rises in some T-helper type 1 markers than placebo. With VRI-003, the change in interferon gamma in runners was about twice that on placebo but not statistically significant (p = 0.07), and in children it rose from baseline. These marker changes have not been shown to cause any symptom finding.
Antioxidant activity of strain ME-3
ME-3 was selected because it showed antioxidant activity in laboratory tests. In small human studies it was linked to higher blood antioxidant markers, but plain goat milk raised some of the same markers and the capsule study gave no direct comparison with placebo. How the bacteria could cause such changes has not been worked out in people.
Clinical trials
Double-blind, placebo-controlled crossover trial over 4 months of winter training; freeze-dried PCC (strain VRI-003) in gelatin capsules at 1.26 x 10^10 a day versus capsules with an inert excipient; stated objective was enhancement of mucosal immunity, and the listed main outcome measures included performance, immunity and respiratory illness, with no single primary named in the abstract; funding and registry not given in the abstract (Cox et al. 2010, Br J Sports Med)
20 healthy elite male distance runners in Australia.
Salivary IgA and IgA1, IL-4 and IL-12 did not differ between treatments. Runners reported 30 days of respiratory symptoms during the probiotic period versus 72 on placebo (p < 0.001), and illness severity was lower without reaching significance (p = 0.06). The change in whole-blood interferon gamma was about twofold that on placebo, not statistically significant (p = 0.07). Running performance did not change substantially.
Double-blind, randomized, placebo-controlled trial; one capsule of at least 1 x 10^9 CFU of VRI-003 PCC a day versus microcrystalline cellulose for 11 weeks; primary aim was upper respiratory and gut symptoms; funded by Chr. Hansen, Probiomics and the Australian Institute of Sport, with one author employed by each company; registered ACTRN12611000006943 (West et al. 2011, Nutr J)
99 competitive cyclists (64 men, 35 women), average age about 35; 88 completed and were analyzed.
The effect on upper respiratory symptoms had too much uncertainty for a decisive outcome. Mild gut symptom episodes and their duration were about twice as great on the probiotic. In men, lower respiratory symptom load was 0.31 times placebo (99% CI 0.07 to 0.96) and gut symptom severity was lower; in women, lower respiratory load was 2.2-fold higher with a very wide interval (0.41 to 27). These sex-specific results are subgroups.
Randomized, double-blind, placebo-controlled trial; 1 x 10^9 L. fermentum PCC (supplied by Probiomics) or placebo twice daily for 8 weeks, final check at 16 weeks; the abstract's methods print the code VRI-033 and its conclusion VRI-003; a companion paper reported immune markers from the same children (Weston et al. 2005, Arch Dis Child)
56 children aged 6 to 18 months in Perth, Australia; 53 completed (26 probiotic, 27 placebo).
The primary outcome was severity and extent by the SCORAD index. Scores fell over time in the probiotic group (p = 0.03) but not in the placebo group; the abstract gives no direct between-group test of the scores. At week 16, 92% versus 63% had a score better than baseline (p = 0.01). Interferon gamma responses rose from baseline only on the probiotic. A disease population, not healthy children.
Single-center, double-blind, placebo-controlled parallel trial of PCC L. fermentum, 2 capsules twice daily (2 x 10^9 CFU each) for 10 weeks; one author is the strain's patent inventor; funding not stated in the abstract (Simons et al. 2006, Nutr Metab Cardiovasc Dis)
46 adults in Australia with total cholesterol of 4 mmol/L or higher.
LDL cholesterol fell 7.0% on the probiotic and 5.2% on placebo, with no significant change over time or difference between groups. Total cholesterol, HDL and triglycerides did not change, nor did liver enzymes or other safety tests. One person withdrew because of bowel discomfort and three others reported it.
Randomized, double-blind, placebo-controlled trial of strain CECT5716, 1 x 10^10 CFU/day, or methylcellulose placebo for 2 weeks before and 2 weeks after an intramuscular flu vaccine, in 31 men and 19 women; first author from the company Puleva Biotech (Olivares et al. 2007, Nutrition)
50 healthy adults, average age 33.
Two weeks after vaccination the share of natural killer cells rose in the probiotic group but not in the placebo group, and the probiotic group had larger rises in some T-helper type 1 markers. Flu-specific IgA rose in the probiotic group, while no antibody response could be detected in the placebo group; flu-specific IgM did not change. Influenza-like illness over the next 5 months was reported as lower, with no statistics in the abstract. Immune markers in a small group, not a test of flu protection.
Randomized, double-blind, controlled trial of follow-on formula with strain CECT5716 plus galactooligosaccharides versus the same formula with galactooligosaccharides only; main outcome was the incidence of infections over 6 months. The abstract also reports a 27% lower rate of upper respiratory tract infections and 30% fewer infections in total, but prints the same 95% CI (0.46 to 1.38, crossing 1) for both, which does not fit their p values (0.026 and 0.003); an erratum was later published (Maldonado et al. 2012, J Pediatr Gastroenterol Nutr)
Infants enrolled at 6 months of age and fed formula until 12 months, in Spain.
The probiotic formula group had a 46% lower rate of gut infections (rate ratio 0.54, 95% CI 0.307 to 0.950, P = 0.032). The other infection results are uncertain because their published statistics do not fit together. Formula-fed babies are a population that does not transfer to adults taking capsules.
Randomized, double-blind, placebo-controlled trial of strain MN-LF23 (sachets of 1 x 10^10 CFU) taken 2 hours after the medicines during 14 days of standard quadruple therapy and for 4 weeks after; two authors affiliated with Mengniu Dairy, and the authors declared no competing interests; registered ChiCTR220059817 (Zhao et al. 2025, Nutr J)
94 adults with confirmed H. pylori infection in China (47 per group).
The probiotic did not improve eradication (82.98% vs 85.11% on placebo, P = 1). Digestive symptom scores (GSRS), constipation and indigestion were lower in the probiotic group than on placebo, and some gut bacteria rose. Inflammatory markers did not differ. The strain was an add-on to prescription drugs in people with a diagnosed infection, so this is not a test of the strain on its own.
Randomized, double-blind, placebo-controlled trial; three capsules twice daily (8.4 log CFU per capsule, stated daily dose 9.2 log CFU) versus identical capsules of saccharose and microcellulose for 3 weeks; registered ISRCTN53164826, with no primary outcome listed in the registry or paper; funded by Estonian Science Foundation, Estonian Technology Agency and EU grants; four authors (Songisepp, Kullisaar, Zilmer and Mikelsaar) share the strain's patent application (Songisepp et al. 2005, Nutr J)
24 healthy adults aged 40 to 60 in Estonia (12 per group); one member of the probiotic group was withdrawn with a respiratory infection.
Total stool lactobacilli rose from baseline with ME-3 and not with placebo, but ME-3 itself was not detected in stool. Blood total antioxidative activity and status rose from baseline; the extra rise over placebo was 4% and 2.5%, with no between-group test reported. The glutathione redox ratio did not change. No adverse effects on general welfare or gut function were recorded. Lab markers, not health outcomes.
Open study, randomization not described in the abstract: 150 g/day of goat milk fermented with ME-3 versus plain goat milk for 21 days; a 2005 report from the same group describes an open goat milk study of the same size, group split, dose and length, in which the fermented milk also contained two supporting strains (L. plantarum LB-4 and L. buchneri); University of Tartu group that developed the strain (Kullisaar et al. 2003, Br J Nutr)
21 healthy adults in Estonia (16 fermented goat milk, 5 plain goat milk; mean age 50 in the 2005 report).
The abstract reports that the fermented milk prolonged the resistance of lipoproteins to oxidation, lowered peroxidized lipoproteins, oxidized LDL, urinary 8-isoprostanes and the glutathione redox ratio, and raised total antioxidative activity. The 2005 report found that plain goat milk also raised antioxidant activity and lowered the glutathione redox ratio. Because the comparator was unfermented milk, the study tests the fermented product, not the strain alone.
Randomized double-blind controlled trial with four groups: 3 x 10^9, 6 x 10^9 or 9 x 10^9 CFU/day of strain CECT5716, or maltodextrin placebo, for 3 weeks. Main outcome: Staphylococcus counts in breast milk; breast pain scores were a secondary outcome. Most authors, including the first, were from the strain's maker, Biosearch Life (Maldonado-Lobón et al. 2015, Breastfeed Med)
Lactating women with painful breastfeeding.
Staphylococcus counts fell from baseline in the probiotic groups while the placebo group stayed similar, and breast pain scores were lower in each probiotic group than placebo. The three doses had similar effects, so no dose response was seen. The trial was run by the strain's maker.
Randomized, double-blind, placebo-controlled parallel trial; 200 ml a day of kefir containing ME-3 (8 x 10^9 CFU/day) versus the same kefir made without the strain, for 8 weeks; primary outcomes named in the paper LDL cholesterol and triglycerides; registered ISRCTN49744186 in 2014, after the trial began, with oxidized LDL and urinary isoprostanes also listed as primary outcomes; analysis of completers only; funded by the European Regional Development Fund, the Estonian Ministry of Education and Research and the University of Tartu; all authors from the University of Tartu, which holds a US patent on the strain, and three of them (Mikelsaar, Kullisaar and Zilmer) are named on that patent; not PubMed-indexed (Mikelsaar et al. 2015, BMC Nutr)
164 clinically healthy Estonian adults aged 35 to 65 with borderline-high LDL cholesterol or high triglycerides were randomized (83 kefir with ME-3, 81 plain kefir); 137 were measured at 4 weeks and 76 (43 and 33) at 8 weeks.
At 4 weeks, lipid profiles were mostly similar between groups, though triglycerides and oxidized LDL fell within the ME-3 group. At 8 weeks, among completers, LDL cholesterol fell 5%, triglycerides 17% and oxidized LDL 6% in the ME-3 group, and these changes differed from plain kefir (P = 0.037, 0.044 and 0.0002); total cholesterol rose in the plain kefir group. More than half of those randomized did not finish, only completers were analyzed, and diet was not recorded. Urinary isoprostanes, a registered primary outcome, were not reported. Body mass index, blood pressure and glucose did not change.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Limosilactobacillus fermentum (Lactobacillus fermentum)
Is Limosilactobacillus fermentum the same as Lactobacillus fermentum?
Yes. In 2020 microbiologists split the large Lactobacillus genus into 25 genera based on genetics, and L. fermentum moved to the new genus Limosilactobacillus. The bacteria did not change, so older studies and labels that say Lactobacillus fermentum describe the same species.
Will any L. fermentum supplement give the results from these studies?
No one can say that. Each trial tested a named strain, such as ME-3, CECT5716, VRI-003 (PCC) or MN-LF23, at a set dose and in a specific group of people. Strains of the same species can behave differently, so a product that lists only "L. fermentum" or a different strain code is not backed by these results. Check the label for the strain code and the CFU count.
Does L. fermentum lower cholesterol?
It depends on the strain, and the results are blood markers only. A 10 week placebo-controlled trial of strain PCC found no difference from placebo in LDL or other blood fats. In an 8 week trial of kefir with strain ME-3, LDL and triglycerides fell more than with plain kefir, but fewer than half of those enrolled finished. A product combining ME-3 with red yeast rice was tested without a comparison group, and its registered placebo comparison has not been published. Anyone managing cholesterol should work with their doctor.
What has L. fermentum been studied for in breastfeeding women?
Strain CECT5716 has been studied in nursing women. In a maker-run trial in women with painful breastfeeding, the main outcome was Staphylococcus counts in milk; breast pain scores, a secondary outcome, were lower than with placebo after 3 weeks. Europe's food safety authority concluded in its review that a cause and effect link to lower breast infection risk had not been established. In a trial in women who already had mastitis, the strain was compared with antibiotics, not placebo. Breast pain with fever, redness or a hard lump needs prompt medical care; a probiotic is not a substitute for it.
What is Limosilactobacillus fermentum?
Limosilactobacillus fermentum, formerly Lactobacillus fermentum, is a lactic acid bacterium sold as named strains, and the research is strain by strain, so a result for one strain does not carry over to another.
What is Limosilactobacillus fermentum used for?
NutraSmarts does not list Limosilactobacillus fermentum under a health category. What the research covers: In a double-blind, placebo-controlled crossover over 4 months of winter training, 20 elite male runners taking strain VRI-003 at a daily dose of 1.26 x 10^10 reported 30 days of respiratory symptoms on the strain versus 72 on placebo.
What is the recommended dosage of Limosilactobacillus fermentum?
The clinically studied dose is Strain-specific: 1 x 10^9 to 1.26 x 10^10 CFU/day of VRI-003 (PCC) in athletes; 1 x 10^10 CFU/day of CECT5716 around flu vaccination; 1 x 10^9 to 9 x 10^9 CFU/day of CECT5716 in nursing women; about 1. Always follow the product label and check with a healthcare provider for personal advice.
Is Limosilactobacillus fermentum safe, and does it have side effects?
Side effects and cautions reported for Limosilactobacillus fermentum include: In an 11-week cyclist trial, the number and duration of mild gut symptom episodes were about twice as great on strain VRI-003 as on placebo. In a 10-week trial of strain PCC, one of 46 people withdrew because of bowel discomfort and three others reported it; liver enzymes and oth… It may also interact with some medications. Limosilactobacillus fermentum is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.
Does Limosilactobacillus fermentum interact with any medications?
Possible interactions include: Antibiotics can kill live probiotic bacteria; in the H. pylori trial the probiotic was taken 2 hours after the medicines. Separate the doses. Immunosuppressant drugs: ask your doctor before using a live probiotic. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Limosilactobacillus fermentum?
NutraSmarts rates the evidence for Limosilactobacillus fermentum as Limited (2 out of 5). It is backed by 11 study summaries and 19 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(19 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Oral administration of the probiotic Lactobacillus fermentum VRI-003 and mucosal immunity in endurance athletes. Br J Sports Med. 2010;44(4):222-6. doi: 10.1136/bjsm.2007.044628.PubMedUsed to support: Double-blind, placebo-controlled crossover trial over 4 months of winter training in 20 healthy elite male distance runners given PCC (strain VRI-003) at 1.26 x 10^10 a day as freeze-dried powder in capsules. The stated objective was to enhance mucosal immunity: salivary IgA, IgA1, IL-4 and IL-12 did not differ between treatments. Respiratory symptom days were 30 on PCC versus 72 on placebo (p < 0.001); illness severity was lower but not significantly (p = 0.06), and the change in whole-blood interferon gamma was about twofold greater, also not significant (p = 0.07). Respiratory illness was one of several listed main outcome measures. Running performance did not change substantially. Funding is not stated in the abstract.
- Lactobacillus fermentum (PCC®) supplementation and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in athletes. Nutr J. 2011;10:30. doi: 10.1186/1475-2891-10-30.PubMedUsed to support: Double-blind randomized trial in 99 competitive cyclists (64 men, 35 women; 88 analyzed) given at least 1 x 10^9 CFU of L. fermentum VRI-003 PCC or placebo daily for 11 weeks; the primary aim was upper respiratory and gut symptoms. The effect on upper respiratory illness was too uncertain for a decisive outcome, and mild gut symptom episodes were about twice as frequent on the probiotic. In men, lower respiratory symptom load was 0.31 times placebo (99% CI 0.07 to 0.96); in women it was 2.2-fold higher with a very wide interval (0.41 to 27). Stool lactobacilli rose 7.7-fold more in men. Funded by Chr. Hansen, Probiomics and the Australian Institute of Sport; one author worked full time for Chr. Hansen and one for Probiomics. Registered ACTRN12611000006943.
- Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition. 2007;23(3):254-60. doi: 10.1016/j.nut.2007.01.004.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 50 healthy adults (31 men, 19 women) given strain CECT5716 (1 x 10^10 CFU/day) or methylcellulose placebo for 2 weeks before and 2 weeks after an intramuscular flu vaccine. Natural killer cells rose in the probiotic group but not the placebo group, some T-helper type 1 markers rose more, and flu-specific IgA rose in the probiotic group while no antibody response was detected on placebo; flu-specific IgM did not change. Influenza-like illness over the next 5 months was reported as lower, with no statistics in the abstract. The first author was from the company Puleva Biotech.
- Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012;54(1):55-61. doi: 10.1097/MPG.0b013e3182333f18.PubMedUsed to support: Randomized double-blind trial in infants aged 6 to 12 months fed a follow-on formula with strain CECT5716 plus galactooligosaccharides, or the same formula with galactooligosaccharides only, for 6 months. The probiotic formula group had a 46% lower rate of gut infections, a 27% lower rate of upper respiratory infections and 30% fewer infections in total. The abstract gives the same confidence interval (0.46 to 1.38, crossing 1) for both the respiratory and the total result, which does not fit their reported p values of 0.026 and 0.003; an erratum to the paper was later published. Evidence in formula-fed infants only.
- Impact of supplementing Limosilactobacillus fermentum MN-LF23 on the eradication of Helicobacter pylori with 14-day standard quadruple therapy: a randomized, double-blind, placebo-controlled trial. Nutr J. 2025;24(1):106. doi: 10.1186/s12937-025-01124-6.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 94 adults with H. pylori infection taking strain MN-LF23 (sachets of 1 x 10^10 CFU) or placebo during 14 days of standard quadruple therapy and for 4 weeks after. Eradication rates did not differ (82.98% probiotic vs 85.11% placebo). The probiotic group had lower digestive symptom scores (GSRS) and less constipation and indigestion. The probiotic was taken 2 hours after the medicines. Two authors were affiliated with Mengniu Dairy; the authors declared no competing interests. Registered ChiCTR220059817.
- Evaluation of the functional efficacy of an antioxidative probiotic in healthy volunteers. Nutr J. 2005;4:22. doi: 10.1186/1475-2891-4-22.PubMedUsed to support: Two 3 week trials of strain ME-3 in healthy volunteers: an open study of ME-3 fermented goat milk versus plain goat milk (21 people; the milk also contained two supporting strains) and a double-blind randomized placebo-controlled study of ME-3 capsules at 9.2 log CFU/day (24 people; ISRCTN53164826). Fecal lactobacilli and blood total antioxidative activity and status rose from baseline with both forms; in the capsule study the extra rise over placebo was 4% and 2.5%, with no between-group test reported. The glutathione redox ratio fell with both fermented and plain goat milk and not with capsules. ME-3 was recovered from stool only in the milk group. Four authors share the strain's patent application; funded by Estonian and EU research grants.
- Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects. Br J Nutr. 2003;90(2):449-56. doi: 10.1079/bjn2003896.PubMedUsed to support: Pilot study in 21 healthy adults assigned to goat milk or goat milk fermented with ME-3 (150 g/day) for 21 days. The abstract reports that the fermented milk prolonged lipoprotein resistance to oxidation, lowered peroxidized lipoproteins, oxidized LDL, 8-isoprostanes and the glutathione redox ratio, and raised total antioxidative activity, and changed stool lactic acid bacteria. Blood and urine oxidation markers only; the comparator was unfermented milk.
- Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis. 2006;16(8):531-5. doi: 10.1016/j.numecd.2005.10.009.PubMedUsed to support: Double-blind, placebo-controlled trial in 46 adults with total cholesterol of 4 mmol/L or more, given L. fermentum PCC capsules (2 capsules twice daily, 2 x 10^9 CFU each) or placebo for 10 weeks. LDL cholesterol fell 7.0% on the probiotic and 5.2% on placebo, with no significant difference; total cholesterol, HDL and triglycerides did not change. One person withdrew for bowel discomfort and three others reported it; liver enzymes and safety tests did not change. One author is the inventor named on the strain's patent.
- Lactobacillus fermentum CECT 5716 Reduces Staphylococcus Load in the Breastmilk of Lactating Mothers Suffering Breast Pain: A Randomized Controlled Trial. Breastfeed Med. 2015;10(9):425-32. doi: 10.1089/bfm.2015.0070.PubMedUsed to support: Randomized double-blind trial in nursing women with painful breastfeeding: strain CECT5716 at 3, 6 or 9 x 10^9 CFU/day or placebo for 3 weeks. The main outcome, Staphylococcus counts in breast milk, fell from baseline in the probiotic groups while the placebo group stayed similar; breast pain scores, a secondary outcome, differed from placebo in all three probiotic groups. The three doses worked alike, so no dose response was seen. Most authors, including the first, were from Biosearch Life, the strain's maker.
- Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis. 2010;50(12):1551-8. doi: 10.1086/652763.PubMedUsed to support: Randomized trial in 352 nursing women with infectious mastitis: strain CECT5716 (124 women) or L. salivarius CECT5713 (127 women) at 9 log CFU/day for 3 weeks, or antibiotics prescribed by their primary care centers (101 women). Breast milk bacterial counts were lower and recovery better in both probiotic groups than in the antibiotic group. No placebo arm; women were under medical care.
- Lactobacillus fermentum CECT 5716 and a reduction of the Staphylococcus load in breast milk which reduces the risk of infectious mastitis: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J. 2017;15(7):e04917. doi: 10.2903/j.efsa.2017.4917.PubMedUsed to support: European Food Safety Authority scientific opinion on a health claim filed by Biosearch Life. The panel found that no conclusions could be drawn from the one study in women without mastitis because of important methodological limits, and that the other two studies, in women who already had mastitis, could not show an effect on how often it develops. It concluded that a cause and effect relationship had not been established.
- The use of probiotic L. fermentum ME-3 containing Reg'Activ Cholesterol supplement for 4 weeks has a positive influence on blood lipoprotein profiles and inflammatory cytokines: an open-label preliminary study. Nutr J. 2016;15(1):93. doi: 10.1186/s12937-016-0213-6.PubMedUsed to support: Open-label study with no control group in 45 adults with borderline-high cardiovascular risk markers taking a multi-ingredient supplement (Reg'Activ Cholesterol) for 4 weeks that contains strain ME-3 (6 x 10^9 bacteria per daily dose) along with 666 mg red yeast rice (10 mg monacolin K), ubiquinol, L-cysteine, vitamin E and B vitamins. Total cholesterol fell from 6.5 to 5.7 mmol/L and oxidized LDL and HbA1c also fell. Without a placebo group the changes cannot be credited to the probiotic. VF Bioscience donated the capsules. The paper calls it an open-label pilot within a larger trial registered as ISRCTN55339917, whose registry entry describes an 8 week comparison with control capsules; that registry links only this open-label study as its results, so no placebo-controlled comparison has been published.
- A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 2020;70(4):2782-2858. doi: 10.1099/ijsem.0.004107.PubMedUsed to support: The 2020 reclassification that split the old genus Lactobacillus into 25 genera, including the new genus Limosilactobacillus. This is why Lactobacillus fermentum is now named Limosilactobacillus fermentum; the bacteria themselves did not change.
- Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005;90(9):892-7. doi: 10.1136/adc.2004.060673.PubMedUsed to support: Randomized double-blind placebo-controlled trial in 56 children aged 6 to 18 months with moderate or severe atopic dermatitis (53 completed), given 1 x 10^9 L. fermentum PCC from Probiomics or placebo twice daily for 8 weeks. The methods name the strain VRI-033 and the conclusion VRI-003; the supplier and trade name match PCC. SCORAD fell over time in the probiotic group (p = 0.03) but not the placebo group, and at week 16, 24 (92%) versus 17 (63%) children scored better than baseline (p = 0.01). Only the abstract was read; it does not give a direct between-group score test or the funding.
- Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy. 2005;35(12):1557-64. doi: 10.1111/j.1365-2222.2005.02376.x.PubMedUsed to support: Immune-marker report from the same trial of L. fermentum PCC in 53 children with atopic dermatitis (26 probiotic, 27 placebo). Interferon gamma responses to two stimuli rose from baseline in the probiotic group at week 8 and week 16, with no significant change on placebo, and the rise correlated with the fall in severity (r = -0.445). Allergen-specific and vaccine responses were largely unchanged. These are blood cell markers, not clinical outcomes.
- Probiotic bacterium: Lactobacillus fermentum. US patent application US20060067921A1. Google Patents. 2006;US20060067921A1, published 30 March 2006; accessed 2026..SourceUsed to support: Patent document, not PubMed-indexed, read in 2026. It names Patricia Conway as inventor and VRI Biomedical Ltd as original assignee, and describes the VRI 003 strain with deposit number NM02/31074. It supports the maker tie of the lipid trial author; it is not health evidence.
- Probiotics: Usefulness and Safety. NCCIH (NIH). 2019;Web page, updated August 2019; accessed 2026..SourceUsed to support: Government health page, not PubMed-indexed, read in 2026. It says the risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems, that severe or fatal infections have been reported in premature infants given probiotics, and that the FDA has warned health care providers about this risk.
- Regulation of plasma lipid profile by Lactobacillus fermentum (probiotic strain ME-3 DSM14241) in a randomised controlled trial of clinically healthy adults. BMC Nutr. 2015;1:27. doi: 10.1186/s40795-015-0020-z.SourceUsed to support: Not PubMed-indexed; open-access full text read. Randomized, double-blind, placebo-controlled trial (ISRCTN49744186) in 164 Estonian adults with borderline-high LDL cholesterol or triglycerides given 200 ml/day of Hellus kefir with ME-3 (8 x 10^9 CFU/day) or the same kefir without it for 8 weeks; the paper names LDL cholesterol and triglycerides as primary outcomes; the registry record, created in 2014 after the trial began, also lists oxidized LDL and urinary isoprostanes as primary, and isoprostanes were not reported. Among the 76 completers at 8 weeks, LDL cholesterol fell 5%, triglycerides 17% and oxidized LDL 6% with ME-3, changes that differed from plain kefir (P = 0.037, 0.044 and 0.0002). Two people per group reported gut symptoms. Publicly funded; the University of Tartu holds the strain patent and three authors are named inventors. Also reports bile salt hydrolase activity of ME-3 in a plate test.
- Effect of novel probiotic food supplement on elevated cardiometabolic and inflammatory markers on clinically asymptomatic volunteers (ISRCTN55339917). ISRCTN registry. 2026;Registry record accessed 2026. doi: 10.1186/ISRCTN55339917.SourceUsed to support: Not PubMed-indexed; registry record read through the ISRCTN API in 2026. Describes a randomized trial of Reg'Activ Cholesterol (two capsules a day, containing strain ME-3) versus control capsules for 8 weeks in adults aged 40 to 70 with raised lipid, glucose or inflammation markers, run October 2014 to March 2015. It gives a final enrollment of 45 and links as its only results the 4 week open-label study of 45 people, so no placebo-controlled comparison from this registration has been published.